uniQure (QURE) announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy for the treatment of Fabry disease. Additionally, the Independent Data Monitoring Committee, IDMC, reviewed safety data from the initial two patients enrolled in the first cohort. The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial
- uniQure price target raised to $70 from $25 at H.C. Wainwright
- uniQure call volume above normal and directionally bullish
- uniQure prices 4.4M shares at $17.00 in public offering
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results